摘要目的: 探讨子宫内膜癌患者血清miR-9-5p,miR-576-5p表达与临床病理特征以及预后的关系。方法: 招募2018年1月至2021年1月我院收治的98例子宫内膜癌患者(子宫内膜癌组)和同期72例于妇产科体检的健康女性(对照组)。采集外周静脉血,应用实时荧光定量聚合酶链反应(RT-PCR)检测血清miR-9-5p,miR-576-5p表达,比较不同病理特征患者血清miR-9-5p,miR-576-5p表达差异。出院后定期随访,统计3年总生存(OS)情况。结果: 子宫内膜癌组血清miR-9-5p表达低于对照组(0.86±0.21 vs 2.55±0.93,t=-17.412,P<0.05),miR-576-5p表达高于对照组(3.42±1.16 vs 1.57±0.45, t=12.833,P<0.05)。FIGO分期Ⅲ~Ⅳ期、低分化、深层肌层浸润、淋巴结转移、远处转移子宫内膜癌患者血清miR-9-5p表达低于FIGO分期Ⅰ~Ⅱ期、中高分化、浅层肌层浸润、无淋巴结转移、无远处转移患者(P<0.05),miR-576-5p表达高于FIGO分期Ⅰ~Ⅱ期、中高分化、浅层肌层浸润、无淋巴结转移、无远处转移患者(P<0.05)。随访3年,2例失访,死亡36例,存活60例。miR-9-5p低表达子宫内膜癌患者3年OS率低于miR-9-5p高表达子宫内膜癌患者(P<0.05),miR-576-5p高表达子宫内膜癌患者3年OS率低于miR-576-5p低表达子宫内膜癌患者(P<0.05)。淋巴结转移、远处转移、高miR-576-5p是子宫内膜癌死亡的危险因素[HR(95%CI):1.921(1.179~3.130)、2.050(1.121~3.750)、1.683(1.162~2.439),P<0.05],miR-9-5p高表达是保护因素[HR(95%CI):0.670(0.497~0.905),P<0.05]。结论: 子宫内膜癌患者血清miR-9-5p表达下调,miR-576-5p表达上调,且与恶性病理特征、不良预后有关。
Abstract：Objective: To investigate the relationship between expression of serum miR-9-5p and miR-576-5p with clinicopathological features and prognosis in patients with endometrial cancer. Methods: A total of 98 patients with endometrial cancer admitted to the department of obstetrics and gynecology of our hospital from January 2018 to January 2021 (endometrial cancer group) and 72 healthy women who underwent physical examination in the department of obstetrics and gynecology during the same period (control group) were recruited. Peripheral venous blood was collected, and the expressions of miR-9-5p and miR-576-5p in serum were detected by real-time fluorescent quantitative polymerase chain reaction (RT-PCR), and the differences in expressions of serum miR-9-5p and miR-576-5p of patients with different pathological characteristics were compared. The 3-year overall survival (OS) was measured by regular follow-up after discharge. Results: The expression of miR-9-5p in endometrial carcinoma group was significantly lower than that in control group (0.86±0.21 vs 2.55±0.93, t=-17.412, P<0.05), and the expression of miR-576-5p was significantly higher than that of control group (3.42±1.16 vs 1.57±0.45, t=12.833, P<0.05). Significantly lower serum miR-9-5p expression and higher miR-576-5p were detected in endometrial cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) stages Ⅲ- Ⅳ, low differentiation, deep muscle infiltration, lymph node metastasis, and distant metastasis compared to those with FIGO stages Ⅰ~Ⅱ, medium-highly differentiation, shallow muscle infiltration, no lymph node metastasis, and no distant metastasis (all P<0.05). After 3 years of follow-up, 2 cases were lost to follow-up, 36 died and 60 survived. The 3-year OS rate of endometrial cancer patients with low expression of miR-9-5p was significantly lower than that of endometrial cancer patients with high expression of miR-9-5p (P<0.05); the 3-year OS rate of endometrial cancer patients with high expression of miR-576-5p was significantly lower than that of endometrial cancer patients with low expression of miR-576-5p (P<0.05). Lymph node metastasis, distant metastasis and high miR-576-5p were risk factors for death of endometrial cancer (HR [95%CI]: 1.921 [1.179~3.130], 2.050 [1.121~3.750], 1.683 [1.162~2.439], P＜0.05), and high expression of miR-9-5p was protective factor (HR [95%CI]: 0.670 [0.497~0.905], P＜0.05). Conclusion: The down-regulated miR-9-5p and up-regulated miR-576-5p are found in patients with endometrial carcinoma, which are related to malignant pathological features and poor prognosis.
杜林, 杜晓艳. 血清miR-9-5p miR-576-5p水平在子宫内膜癌中的表达及临床意义[J]. 河北医学, 2025, 31(3): 415-419.
DU Lin, DU Xiaoyan. Expression of Serum miR-9-5p and miR-576-5p in Patients with Endometrial Cancer and the Clinical Significances. HeBei Med, 2025, 31(3): 415-419.
[1] Crosbie EJ,Kitson SJ,Mcalpine JN,et al.Endometrial cancer[J].Lancet,2022,399(10333):1412-1428. [2] Shetty A,Venkatesh T,Kabbekodu SP,et al.LncRNA-miRNA-mRNA regulatory axes in endometrial cancer:a comprehensive overview[J].Arch Gynecol Obstet,2022,306(5):1431-1447. [3] Wei YQ,Jiao XL,Zhang SY,et al.MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5[J].Eur Rev Med Pharmacol Sci,2019,23(17):7314-7326. [4] Jin L,Li X,Zhao Y,et al.miR-576-5p facilitates aggressive cell behaviors in colon adenocarcinoma via targeting NEGR1[J].Crit Rev Eukaryot Gene Expr,2022,32(7):25-33. [5] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(第4版)[J].中国实用妇科与产科杂志,2018,34(8):880-886. [6] Ye Z,Jiang Y,Wu J.A novel necroptosis-associated miRNA signature predicting prognosis of endometrial cancer and correlated with immune infiltration[J].Taiwan Obstet Gynecol,2023,62(2):291-298. [7] Wang J,Wang B,Ren H,et al.miR-9-5p inhibits pancreatic cancer cell proliferation,invasion and glutamine metabolism by targeting GOT1[J].Biochem Biophys Res Commun,2019,509(1):241-248. [8] 黄振宇,杨剑波,凌雪君,等.LncRNA Hulc和miR-9-5p在乳腺癌中的表达水平及临床意义[J].中国肿瘤外科杂志,2020,12(4):360-365. [9] Luo J,Liu L,Shen J,et al.miR-576-5p promotes epithelial-to-mesenchymal transition in colorectal cancer by targeting the Wnt5a-mediated Wnt/β-catenin signaling pathway[J].Mol Med Rep,2021,23(2):94. [10] Wu Y,Zhou J,Li Y,et al.Hsa_circ_0001445 works as a cancer suppressor via miR-576-5p/SFRP1 axis regulation in ovarian cancer[J].Cancer Med,2023,12(5):5736-5750. [11] Chen C,Zhang Q,Kong B.miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4[J].Clin Transl Oncol,2023,25(3):706-720.
2025, Vol. 31 
冀公网安备13080202000786号